Arcutis Biotherapeutics
ARQT
102 hedge funds and large institutions have $1.19B invested in Arcutis Biotherapeutics in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 40 increasing their positions, 25 reducing their positions, and 15 closing their positions.
525% more call options, than puts
Call options by funds: $4.36M | Put options by funds: $698K
60% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 25
53% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 15
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
9% more funds holding
Funds holding: 94 → 102 (+8)
2.95% less ownership
Funds ownership: 93.51% → 90.57% (-2.9%)
12% less capital invested
Capital invested by funds: $1.35B → $1.19B (-$160M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.56M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$6.37M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.2M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$3.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$59.4M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$8.75M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$4.35M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$3.39M |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
-$3.29M |
ARQT Hedge Fund Activity: Q2 2021 in Review
102 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q2 2021, worth a combined $1.19B — down 12% from $1.35B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ARQT positions and 15 closed out — a net gain of 8 holders — while 40 added to existing stakes and 25 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $12.9M. The largest seller was Frazier Management, cutting an estimated $59.4M.
- 102 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q2 2021, up from 94 in Q1 2021.
- Funds reported $1.19B of Arcutis Biotherapeutics stock for Q2 2021, down 12% quarter-over-quarter.
- 23 funds opened new Arcutis Biotherapeutics positions in Q2 2021 and 15 closed out, a net change of +8 holders.
- The largest Arcutis Biotherapeutics buyer in Q2 2021 was Point72 Asset Management, an estimated $12.9M added.
- The largest Arcutis Biotherapeutics seller in Q2 2021 was Frazier Management, an estimated $59.4M sold.
Based on aggregated 13F filings for Q2 2021.